The New England Journal of Medicine (NEJM) is the world’s leading medical journal and website. Published continuously for over 200 years, NEJM delivers high-quality, peer-reviewed research and interactive clin
A new study published in theNew England Journal of Medicinereveals that semaglutide significantly improves outcomes for patients with a serious form of liver disease, benefiting approximately two-thirds of those treated. The findings come from the ESSENCE phase 3 clinical trial, a placebo-controlled s...
A new study published in theNew England Journal of Medicineand presented at Obesity Week 2022 has found that the drug semaglutide is effective in helping adolescents who are obese or overweight lose weight and improve their cardiovascular health. In an international phase 3a clinical trial, adolescen...
including approval late last month of Wegovy, a weekly injection, for use in children ages 12 and older. Different doses of the drug, called semaglutide, are also used under different names to treat diabetes.A recent studypublished in the New England Journal of Medicine found that W...
#今日行业热点#①The New England Journal of Medicine:Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma 帕博利珠单抗(Pembrolizumab)对比安慰剂辅助用药用于复发风险较高的肾透明细胞癌(CCRCC) DOI: 10.1056/NEJMoa2312695 ②The New England Journal of Medicine:Adjuvant Immunotherapy for Kidney ...
③The New England Journal of Medicine:Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity 临床试验:司美格鲁肽在射血分数保留的心力衰竭合并肥胖患者中的随机、对照试验 DOI: 10.1056/NEJMoa2306963 ④Genome Medicine:Spatial transcriptomics analysis of neoadjuvant cabozantinib ...
③The New England Journal of Medicine:Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction β受体阻滞剂用于射血分数保留型心肌梗死的REDUCE-AMI研究 DOI: 10.1056/NEJMoa2401479 ④Journal for ImmunoTherapy of Cancer:Efficacy of LCMV-based cancer immunotherapies is unleashed by intratumoral...
The trials have been published in high profile journals — the New England Journal of Medicine (STEP 1), The Lancet (STEP 2), and JAMA (STEP 3, STEP 4)— said Robert F. Kushner, MD. "I would encourage all of you to download and read each of these trials on your own," said Kush...
“每周皮下注射一次索马鲁肽可有效减肥,New England Journal of Medicine: ① 纳入1961名肥胖成年人,进行68周的每周一次皮下注射2.4mg索马鲁肽或安慰剂治疗;② 68周后,索马鲁肽组体重平均降低15.3kg(14.9%),安慰剂组降低2.6kg(2.4%);③第68周,索马鲁肽组体重减少5%以上、10%以上及15%以上的比例分别为86.4%、...
Dupixent® (dupilumab) late-breaking data from Notus Confirmatory Phase 3 COPD trial presented at ATS and published in the New England Journal of Medicine. Regeneron Pharmaceuticals Inc. May 20, 2024. Accessed September 30, 2024. https://investor.regeneron.com/news-releases/news-release-details...